Perry A Karsen - Net Worth and Insider Trading
Perry A Karsen Net Worth
The estimated net worth of Perry A Karsen is at least $6 Million dollars as of 2024-03-28. Perry A Karsen is the see remarks of Celgene Corp and owns about 54,869 shares of Celgene Corp (CELG) stock worth over $6 Million. Perry A Karsen is the Director of Intellia Therapeutics Inc and owns about 5,000 shares of Intellia Therapeutics Inc (NTLA) stock worth over $137,550. Perry A Karsen is also the Director of Jounce Therapeutics Inc and owns about 5,000 shares of Jounce Therapeutics Inc (JNCE) stock worth over $9,400. Besides these, Perry A Karsen also holds OncoMed Pharmaceuticals Inc (OMED) . Details can be seen in Perry A Karsen's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Perry A Karsen has not made any transactions after 2020-12-17 and currently still holds the listed stock(s).
Transaction Summary of Perry A Karsen
Perry A Karsen Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Perry A Karsen owns 9 companies in total, including Jounce Therapeutics Inc () , Intellia Therapeutics Inc () , and Voyager Therapeutics Inc () among others .
Click here to see the complete history of Perry A Karsen’s form 4 insider trades.
Insider Ownership Summary of Perry A Karsen
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
Jounce Therapeutics Inc | 2017-02-01 | director | |
Intellia Therapeutics Inc | 2020-12-17 | director | |
Voyager Therapeutics Inc | 2015-11-10 | director | |
OncoMed Pharmaceuticals Inc | 2019-04-23 | director | |
Navidea Biopharmaceuticals Inc | 2014-11-10 | director | |
Agios Pharmaceuticals Inc | 2013-07-23 | director | |
Adynxx Inc | 2013-11-27 | director | |
Graphite Bio Inc | 2021-06-24 | director | |
Jiya Acquisition Corp | 2020-11-18 | director |
Perry A Karsen Latest Holdings Summary
Perry A Karsen currently owns a total of 4 stocks. Among these stocks, Perry A Karsen owns 54,869 shares of Celgene Corp (CELG) as of November 12, 2014, with a value of $6 Million and a weighting of 97.44%. Perry A Karsen owns 5,000 shares of Intellia Therapeutics Inc (NTLA) as of December 17, 2020, with a value of $137,550 and a weighting of 2.26%. Perry A Karsen also owns 5,000 shares of Jounce Therapeutics Inc (JNCE) as of February 1, 2017, with a value of $9,400 and a weighting of 0.15%. The other 1 stocks OncoMed Pharmaceuticals Inc (OMED) have a combined weighting of 0.15% among all his current holdings.
Latest Holdings of Perry A Karsen
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
CELG | Celgene Corp | 2014-11-12 | 54,869 | 108.24 | 5,939,021 |
NTLA | Intellia Therapeutics Inc | 2020-12-17 | 5,000 | 27.51 | 137,550 |
JNCE | Jounce Therapeutics Inc | 2017-02-01 | 5,000 | 1.88 | 9,400 |
OMED | OncoMed Pharmaceuticals Inc | 2017-06-05 | 10,000 | 0.89 | 8,900 |
Holding Weightings of Perry A Karsen
Perry A Karsen Form 4 Trading Tracker
According to the SEC Form 4 filings, Perry A Karsen has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the sale of 39,420 shares on November 12, 2014, which brought Perry A Karsen around $4 Million.
According to the SEC Form 4 filings, Perry A Karsen has made a total of 1 transactions in Intellia Therapeutics Inc (NTLA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Intellia Therapeutics Inc is the sale of 88,764 shares on December 17, 2020, which brought Perry A Karsen around $5 Million.
According to the SEC Form 4 filings, Perry A Karsen has made a total of 0 transactions in Jounce Therapeutics Inc (JNCE) over the past 5 years. The most-recent trade in Jounce Therapeutics Inc is the acquisition of 5,000 shares on February 1, 2017, which cost Perry A Karsen around $80,000.
More details on Perry A Karsen's insider transactions can be found in the Insider Trading History of Perry A Karsen table.Insider Trading History of Perry A Karsen
- 1
Perry A Karsen Trading Performance
GuruFocus tracks the stock performance after each of Perry A Karsen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Perry A Karsen is 50.42%. GuruFocus also compares Perry A Karsen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Perry A Karsen within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Perry A Karsen's insider trading performs compared to the benchmark.
Performance of Perry A Karsen
Average Relative Return
13.04%
Outperforming Transactions
50%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Relative Return(%) | 13.63 | 50.42 | 4.72 | 13.04 | -49.26 | -28.36 |
Relative Return to S&P 500(%) | 11.15 | 47.59 | -3.57 | -5.28 | -58.22 | -40.64 |
Perry A Karsen Ownership Network
Ownership Network List of Perry A Karsen
Ownership Network Relation of Perry A Karsen
Perry A Karsen Owned Company Details
What does Jounce Therapeutics Inc do?
Who are the key executives at Jounce Therapeutics Inc?
Perry A Karsen is the director of Jounce Therapeutics Inc. Other key executives at Jounce Therapeutics Inc include 10 percent owner Concentra Merger Sub, Inc. , 10 percent owner Concentra Biosciences, Llc , and director & CEO and President Richard /ca/ Murray .
Jounce Therapeutics Inc () Insider Trades Summary
Over the past 18 months, Perry A Karsen made no insider transaction in Jounce Therapeutics Inc (). Other recent insider transactions involving Jounce Therapeutics Inc () include a net sale of 84,298 shares made by Richard /ca/ Murray , a net purchase of 85,987 shares made by Kevin C Tang , and a net sale of 16,634 shares made by Hugh M Cole .
In summary, during the past 3 months, insiders sold 0 shares of Jounce Therapeutics Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 124,313 shares of Jounce Therapeutics Inc () were sold and 85,987 shares were bought by its insiders, resulting in a net sale of 38,326 shares.
Jounce Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.
Jounce Therapeutics Inc Insider Transactions
Perry A Karsen Mailing Address
Above is the net worth, insider trading, and ownership report for Perry A Karsen. You might contact Perry A Karsen via mailing address: C/o Celgene Corporation, 86 Morris Avenue, Summit Nj 07901.